Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.54 |
| ▸ | EDNRA | P25101 | 5/20 | 0.53 |
| ▸ | FABP4 | P15090 | 3/20 | 0.53 |
| ▸ | WDR5 | P61964 | 1/20 | 0.53 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554391 | 0.93 | EDNRA (0.57) | SLC16A3EDNRAHDAC1NR3C1BRD4 | |
| SCHEMBL3562220 | 0.93 | EDNRA (0.52) | SLC16A3EDNRAFABP4HDAC1NR3C1 | |
| SCHEMBL3561717 | 0.86 | SLC16A3 (0.75) | SLC16A3EDNRAFABP4 | |
| SCHEMBL3558731 | 0.84 | EDNRA (0.62) | SLC16A3EDNRAFABP4HDAC1 | |
| SCHEMBL3561271 | 0.84 | SLC16A3 (0.74) | SLC16A3FABP4WDR5FABP5 | |
| SCHEMBL3558893 | 0.83 | SLC16A3 (0.68) | SLC16A3EDNRAFABP4 | |
| SCHEMBL3560333 | 0.78 | PTK2B (0.60) | SLC16A3FABP4WDR5FABP5 | |
| SCHEMBL6243926 | 0.78 | POLB (0.57) | EDNRAHDAC1 | |
| SCHEMBL9137231 | 0.78 | EDNRA (0.77) | EDNRAHDAC1 | |
| SCHEMBL3558846 | 0.76 | TSHR (0.70) | SLC16A3FABP4WDR5FABP5HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885EDNRA 362/4885FABP4 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.